Science Explorer Back to mapMap
Discussion
Topic · Radiology, Nuclear Medicine and Imaging

Radiopharmaceutical Chemistry and Applications

Radiopharmaceutical Chemistry and Applications is a research topic within Radiology, Nuclear Medicine and Imaging. Science Explorer counts 44k research works in it since 1950. 10.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the development, synthesis, and application of radiopharmaceuticals for PET and SPECT imaging, targeted therapy, radioimmunotherapy, and alpha particle therapy in cancer treatment. It covers topics such as coordinating radiometals, chelators, dosimetry, and the use of specific radionuclides for therapeutic purposes.

  • Radiopharmaceuticals
  • PET Imaging
  • Targeted Therapy
  • Radioimmunotherapy
  • Alpha Particle Therapy
  • Chelators
  • Nuclear Medicine
  • Bifunctional Agents
  • Dosimetry
  • Cancer Treatment
Research works
44k
fractional, since 1950
In the world top 10%
4.4k
per year above
Top-10% rate
10.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+10%
the tick is no change
Largest producer
United States
34% of the 10 largest, 2022-now
Radiopharmaceutical Chemistry and Applications

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Radiopharmaceutical Chemistry and Applications research?

By volume, the United States and China publish the most (1.7k and 980 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.7k works
  2. 2 China 980 works
  3. 3 Germany 510 works
  4. 4 Japan 348 works
  5. 5 France 285 works
  6. 6 India 269 works
  7. 7 Italy 269 works
  8. 8 Russia 241 works
  9. 9 United Kingdom 216 works
  10. 10 Canada 179 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 33.7%China: 19.7%Germany: 10.3%Japan: 7.0%6 others listed: 29.3%34%largest
United States1,675 · 33.7%China980 · 19.7%Germany510 · 10.3%Japan348 · 7.0%6 others listed1,459 · 29.3%

Shares of the rows listed above, not of the whole node.

Which institutions lead Radiopharmaceutical Chemistry and Applications research?

By volume in 2022-now, Centre National de la Recherche Scientifique publishes the most Radiopharmaceutical Chemistry and Applications research, followed by Russian Academy of Sciences and Harvard University.

By volume, 2022-now

  1. 1 Centre National de la Recherche ScientifiqueFrance 67 works
  2. 2 Russian Academy of SciencesRussia 66 works
  3. 3 Harvard UniversityUnited States 65 works
  4. 4 Mayo ClinicUnited States 46 works
  5. 5 Memorial Sloan Kettering Cancer CenterUnited States 44 works
  6. 6 Cornell UniversityUnited States 43 works
  7. 7 Helmholtz Association of German Research CentresGermany 41 works
  8. 8 Chinese Academy of SciencesChina 40 works
  9. 9 The University of Texas MD Anderson Cancer CenterUnited States 40 works
  10. 10 Johns Hopkins UniversityUnited States 39 works

Who are the leading researchers in Radiopharmaceutical Chemistry and Applications?

The most-cited researchers publishing on Radiopharmaceutical Chemistry and Applications include Hermann Brenner, Cyrus Cooper and Jun Wang.

  1. 1 Hermann Brenner Germany 343k citations
  2. 2 Cyrus Cooper United Kingdom 342k citations
  3. 3 Jun Wang China 340k citations
  4. 4 Robert A. Weinberg United States 301k citations
  5. 5 Matthew M. Meyerson United States 280k citations
  6. 6 Hagop M. Kantarjian United States 273k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Radiopharmaceutical Chemistry and Applications?

The most cited paper in Radiopharmaceutical Chemistry and Applications is "The nuclear receptor superfamily: The second decade" (David J. Mangelsdorf, Carl S. Thummel, Miguel Beato et al., 1995), with 7,017 citations. Next come "Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ" (4,662) and "Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67." (4,236).

Most cited papers
#PaperReleasedCitations
1 The nuclear receptor superfamily: The second decade David J. Mangelsdorf, Carl S. Thummel, Miguel Beato et al. · Cell Open access Dec 1995 7,017
2 Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ W. David Benton, Ronald W. Davis · Science 8 Apr 1977 4,662
3 Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Johannes Gerdes, Hilmar Lemke, Heinz Baisch et al. · The Journal of Immunology Oct 1984 4,236
4 Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer Scott Arthur Tomlins, Daniel R. Rhodes, Sven Perner et al. · Science 27 Oct 2005 3,908
5 Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer Chris C. Parker et al. · New England Journal of Medicine 17 Jul 2013 3,410
All 100 most cited papers, with filters and sorting

Where is Radiopharmaceutical Chemistry and Applications research done?

The largest centres of Radiopharmaceutical Chemistry and Applications research in 2022-now are Beijing (China), Moscow (Russia), Shanghai (China) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Luzhou.

Largest cities, 2022-now

  1. 1 BeijingChina 178 works
  2. 2 MoscowRussia 138 works
  3. 3 ShanghaiChina 125 works
  4. 4 New YorkUnited States 114 works
  5. 5 LondonUnited Kingdom 92 works
  6. 6 ParisFrance 76 works
  7. 7 MumbaiIndia 70 works
  8. 8 TokyoJapan 66 works
  9. 9 BostonUnited States 64 works
  10. 10 SeoulSouth Korea 62 works

Where it is the local speciality

  1. LuzhouCN · 26.8 works16×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Radiopharmaceutical Chemistry and Applications than the world average.

See Radiopharmaceutical Chemistry and Applications on the map

Where is the best place to study Radiopharmaceutical Chemistry and Applications?

Among universities, judged by research, Cornell University, University of Bern and Harvard University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.99%fractional works in this field (log) →share of work in the world top 10% →The University of Me…Cornell UniversityUniversity of BernHarvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Cornell UniversityUnited States 77.122.6%5.6×43 -7.8%
2University of BernSwitzerland 70.722.0%5.2×17 -1.0%
3Harvard UniversityUnited States 70.611.7%3.5×65 +5.1%
4The University of MelbourneAustralia 69.729.1%2.7×18 +13.3%
5University of California, San FranciscoUnited States 69.521.1%7.6×32 +6.6%
6Erasmus University RotterdamNetherlands 66.920.4%5.5×17 -3.1%
7Johns Hopkins UniversityUnited States 60.914.5%4.2×39 -14.3%
8University of Duisburg-EssenGermany 59.719.1%8.1×19 +5.0%
9National University of SingaporeSingapore 58.822.5%1.5×10 +187.1%
10Ludwig-Maximilians-Universität MünchenGermany 56.916.9%4.8×25 +9.4%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Radiopharmaceutical Chemistry and Applications, country by country

Is Radiopharmaceutical Chemistry and Applications research growing?

Output in 2022-2025 was 10% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Radiopharmaceutical Chemistry and Applications.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Radiopharmaceutical Chemistry and Applications as a percentage of every work published that year, 0.029% in 2024.

still counting0.050%0.10%Radiopharmaceutical Chemistry and Applications0.032% in 202519801990200020102020

Fractional works of Radiopharmaceutical Chemistry and Applications over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Radiopharmaceutical Chemistry and Applications10.2% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Radiopharmaceutical Chemistry and Applications. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.